Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

BACKGROUND: Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR‐mutated NSCLC. This study aimed to investigate the efficacy and safety of PD‐1 blockade with sintilimab plus anti‐angiogenic treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kaiyan, Xu, Yanjun, Huang, Zhiyu, Yu, Xiaoqing, Hong, Wei, Li, Hui, Xu, Xiaoling, Lu, Hongyang, Xie, Fajun, Chen, Jun, Xu, Youzu, Fan, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587987/
https://www.ncbi.nlm.nih.gov/pubmed/37723837
http://dx.doi.org/10.1002/cam4.6548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587987/
https://www.ncbi.nlm.nih.gov/pubmed/37723837
http://dx.doi.org/10.1002/cam4.6548

Ejemplares similares